Therapy Areas: Inflammatory Diseases
PredictImmune Names Paul Kinnon as New Chief Executive Officer
9 July 2018 - - Cambridge, England-based medical testing development company PredictImmune has appointed Paul Kinnon as its new chief executive officer, the company said.
Kinnon joins PredictImmune having spent over 20 years in a number of executive positions in the US and is anticipated to drive the company's next phase of development, commercialisation and expansion.
Following a career start as an analytical chemist at Smithkline French and Beckman Research, a predecessor company of GlaxoSmithKline, Kinnon went on to hold leadership positions with Transgenomic, ZyGEM, Life Technologies, Guava Technologies, and Cellomics.
PredictImmune is developing tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing inflammatory bowel disease.
Based on research at Cambridge University, the company is developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease.
Login
Username:

Password: